scholarly journals Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis-critical role in tumor invasion

2010 ◽  
pp. NA-NA ◽  
Author(s):  
Hiroyuki Hayashi ◽  
Kazuki Nabeshima ◽  
Mikiko Aoki ◽  
Makoto Hamasaki ◽  
Sotaro Enatsu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Invasion ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
Critical Role

scholarly journals Examination of main lymph node (No.253) metastasis in left colorectal cancer: A retrospective analysis of a single-institution cohort

2021 ◽  
Author(s):  
Takefumi Yoshida ◽  
Fumihiko Fujita ◽  
Dai Shida ◽  
Kenichi Koushi ◽  
Kenji Fujiyoshi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
D3 Lymphadenectomy ◽  
Positive Group ◽  
Factors Associated

Abstract Background. The extent of lymph node dissection in advanced colorectal cancer varies according to regional guidelines. D3 lymphadenectomy is routinely performed in Japan but is associated with several risk factors. Metastases of the main lymph nodes (No.253 lymph nodes), which are located at the root of the inferior mesenteric artery, are rare in left-sided colorectal cancer. Tumor depth (T4) is an identifier of No.253 lymph node metastasis (LNM) risk, but other risk factors associated with No.253 LNM are unclear. This study was undertaken to investigate the frequency of No.253 LNM and to identify other clinicopathological risk factors associated with No.253 LNM in left-sided colorectal cancer. In this study, we aimed to evaluate the clinical benefit of routine D3 lymphadenectomy in surgically treated advanced colorectal cancer. Methods. A retrospective database of patients with colorectal cancer who underwent D3 dissection and R0 resection at Kurume University Hospital from 1978 to 2017 was constructed and used to search for the frequency and risk factors of No.253 LNM to investigate long-term prognosis. Clinicopathological factors associated with No.253 LNM, including age, sex, tumor location, T stage, tumor diameter, carcinoembryonic antigen levels, and various dissected lymph nodes, were analyzed. Results. Among 1,614 consecutive patients, No.253 LNM was observed in 23 cases (1.4%). The presence of three or more regional LNMs was an independent risk factor for No.253 LNM (odds ratio: 26.8). The 5-year overall survival rate was 49.1% in the No.253 LNM-positive group and 78.4% in the No.253 LNM-negative group (p=0.002). Conclusion. In left-sided colorectal cancer, No.253 LNM was a poor prognosis factor, and three or more regional LNMs were a risk factor for No.253 LNM. The No.253 LNM-positive group had a poor prognosis, but there are cases of long-term survival, with a 5-year survival rate of 49%. D3 lymphadenectomy is suitable when three or more metastatic LNs are identified prior to surgery.

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

2009 ◽  
Vol 27 (35) ◽  
pp. 5931-5937 ◽  
Author(s):  
Susan D. Richman ◽  
Matthew T. Seymour ◽  
Philip Chambers ◽  
Faye Elliott ◽  
Catherine L. Daly ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Braf Mutation ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
Progression Free Survival ◽  
Predictive Biomarker ◽  
Poor Prognostic Factor ◽  
Minimal Impact ◽  
The Impact

PurposeActivating mutation of the KRAS oncogene is an established predictive biomarker for resistance to anti–epidermal growth factor receptor (anti-EGFR) therapies in advanced colorectal cancer (aCRC). We wanted to determine whether KRAS and/or BRAF mutation is also a predictive biomarker for other aCRC therapies.Patients and MethodsThe Medical Research Council Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing (MRC FOCUS) trial compared treatment sequences including first-line fluorouracil (FU), FU/irinotecan or FU/oxaliplatin in aCRC. Tumor blocks were obtained from 711 consenting patients. DNA was extracted and KRAS codons 12, 13, and 61 and BRAF codon 600 were assessed by pyrosequencing. Mutation (mut) status was assessed first as a prognostic factor and then as a predictive biomarker for the benefit of adding irinotecan or oxaliplatin to FU. The association of BRAF-mut with loss of MLH1 was assessed by immunohistochemistry.ResultsThree hundred eight (43.3%) of 711 patients had KRAS-mut and 56 (7.9%) of 711 had BRAF-mut. Mutation of KRAS, BRAF, or both was present in 360 (50.6%) of 711 patients. Mutation in either KRAS or BRAF was a poor prognostic factor for overall survival (OS; hazard ratio [HR], 1.40; 95% CI, 1.20 to 1.65; P < .0001) but had minimal impact on progression-free survival (PFS; HR, 1.16; 95% CI, 1.00 to 1.36; P = .05). Mutation status did not affect the impact of irinotecan or oxaliplatin on PFS or OS. BRAF-mut was weakly associated with loss of MLH1 staining (P = .012).ConclusionKRAS/BRAF mutation is associated with poor prognosis but is not a predictive biomarker for irinotecan or oxaliplatin. There is no evidence that patients with KRAS/BRAF mutated tumors are less likely to benefit from these standard chemotherapy agents.

Increasing Heme Oxygenase-1-Expressing Macrophages Indicates a Tendency of Poor Prognosis in Advanced Colorectal Cancer

Digestion ◽  
2019 ◽  
Vol 101 (4) ◽  
pp. 401-410
Author(s):  
Shingo Kimura ◽  
Naing Ye Aung ◽  
Rintaro Ohe ◽  
Mitsuhiro Yano ◽  
Toshio Hashimoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Heme Oxygenase ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
Heme Oxygenase 1

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

The Lancet ◽  
2007 ◽  
Vol 370 (9582) ◽  
pp. 143-152 ◽  
Author(s):  
Matthew T Seymour ◽  
Timothy S Maughan ◽  
Jonathan A Ledermann ◽  
Clare Topham ◽  
Roger James ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Randomised Controlled Trial ◽  
Combination Chemotherapy ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
Controlled Trial ◽  
Randomised Controlled ◽  
Patients With Poor Prognosis

scholarly journals Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis

2006 ◽  
Author(s):  
Tomoko Seya ◽  
Noritake Tanaka ◽  
Seiichi Shinji ◽  
Kimiyoshi Yokoi ◽  
Michihiro Koizumi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
Nodal Metastasis

scholarly journals Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients

2007 ◽  
Vol 121 (5) ◽  
pp. 1066-1071 ◽  
Author(s):  
Joan Maurel ◽  
Cristina Nadal ◽  
Xabier Garcia-Albeniz ◽  
Rosa Gallego ◽  
Enric Carcereny ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Matrix Metalloproteinase ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Advanced Colorectal Cancer ◽  
Matrix Metalloproteinase 7 ◽  
Colorectal Cancer Patients

Tu1945 - The Role of Broad-Complex, Tramtrack and Bric-Abrac (BTB) Protein X on Tumor Invasion, Metastasis and Poor Prognosis in Colorectal Cancer

2018 ◽  
Vol 154 (6) ◽  
pp. S-1061
Author(s):  
Hirotada Nishie ◽  
Eiji Kubota ◽  
Hiromi Kataoka ◽  
Shigeki Higashiyama ◽  
Takashi Joh
Keyword(s):  
Colorectal Cancer ◽  
Tumor Invasion ◽  
Poor Prognosis ◽  
Protein X ◽  
Broad Complex

FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer

2012 ◽  
Vol 114 (8) ◽  
pp. 755-762 ◽  
Author(s):  
Xiao-Yuan Chu ◽  
Zi-Man Zhu ◽  
Long-Bang Chen ◽  
Jing-Hua Wang ◽  
Quan-Sheng Su ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Invasion ◽  
Poor Prognosis ◽  
Foxm1 Expression
Sign in / Sign up

Export Citation Format

Share Document